Cargando…

Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review

Background: Prostate-specific membrane antigen (PSMA) is not sufficiently overexpressed in a small proportion of prostate cancer (PCa) patients, who require other strategies for imaging and/or treatment. We reviewed potential targets other than PSMA for PCa theranostics in nuclear medicine that have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gauthé, Mathieu, Sargos, Paul, Barret, Eric, Fromont-Hankard, Gaëlle, Beauval, Jean-Baptiste, Brureau, Laurent, Créhange, Gilles, Renard-Penna, Raphaële, Dariane, Charles, Fiard, Gaëlle, Mathieu, Romain, Roubaud, Guilhem, Ruffion, Alain, Rouprêt, Morgan, Ploussard, Guillaume
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584491/ https://www.ncbi.nlm.nih.gov/pubmed/34768432 http://dx.doi.org/10.3390/jcm10214909

Ejemplares similares

Oncologic Impact and Safety of Pre-Operative Radiotherapy in Localized Prostate and Bladder Cancer: A Comprehensive Review from the Cancerology Committee of the Association Française d’Urologie
por: Sargos, Paul, et al.
Publicado: (2021)

Biomarker in Active Surveillance for Prostate Cancer: A Systematic Review
por: Manceau, Cécile, et al.
Publicado: (2021)

Overview of the Development and Use of Akt Inhibitors in Prostate Cancer
por: Gasmi, Anis, et al.
Publicado: (2021)

Vasectomy and Risk of Prostate Cancer: A Systematic Review and Meta-analysis
por: Baboudjian, Michael, et al.
Publicado: (2022)

Salvage Radical Prostatectomy for Recurrent Prostate Cancer: A Systematic Review (French ccAFU)
por: Saouli, Amine, et al.
Publicado: (2023)

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
por: Teyssonneau, Diego, et al.
Publicado: (2022)

Same-day-discharge Robot-assisted Radical Prostatectomy: An Annual Countrywide Analysis
por: Ploussard, Guillaume, et al.
Publicado: (2021)

A 5-Year Contemporary Nationwide Evolution of the Radical Prostatectomy Landscape
por: Ploussard, Guillaume, et al.
Publicado: (2021)

Clinical Trial Protocol for PERFECT: A Randomised Controlled Trial Comparing the Efficiency and Tolerance of Transperineal Fusion Versus Transrectal Imaging-targeted Prostate Biopsies (CCAFU-PR1 Study)
por: Touzani, Alae, et al.
Publicado: (2022)

Chromogranin A: a useful biomarker in castration-resistant prostate cancer
por: Ploussard, Guillaume, et al.
Publicado: (2022)

(68)Ga-PSMA-11 PET/CT in restaging castration-resistant nonmetastatic prostate cancer: detection rate, impact on patients’ disease management and adequacy of impact
por: Fourquet, Aloÿse, et al.
Publicado: (2020)

PSMA Theranostics: Current Landscape and Future Outlook
por: Zhang, Hanbo, et al.
Publicado: (2021)

Assessment of the Minimal Targeted Biopsy Core Number per MRI Lesion for Improving Prostate Cancer Grading Prediction
por: Ploussard, Guillaume, et al.
Publicado: (2020)

Restaging the Biochemical Recurrence of Prostate Cancer with [(68)Ga]Ga-PSMA-11 PET/CT: Diagnostic Performance and Impact on Patient Disease Management
por: Fourquet, Aloÿse, et al.
Publicado: (2021)

Advances in PSMA theranostics
por: Jeitner, Thomas M., et al.
Publicado: (2022)

Deep Neural Networks Outperform the CAPRA Score in Predicting Biochemical Recurrence After Prostatectomy
por: Sargos, Paul, et al.
Publicado: (2021)

PSMA Theranostics: Science and Practice
por: Mokoala, Kgomotso, et al.
Publicado: (2021)

PSMA expression by microvasculature of thyroid tumors – Potential implications for PSMA theranostics
por: Bychkov, Andrey, et al.
Publicado: (2017)

Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer: A retrospective multicenter study
por: Orré, Mathieu, et al.
Publicado: (2017)

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
por: Jones, Wallace, et al.
Publicado: (2020)

Effect of Carbohydration on the Theranostic Tracer PSMA I&T
por: Schmidt, Alexander, et al.
Publicado: (2018)

PSMA Theranostics: Current Status and Future Directions
por: Rahbar, Kambiz, et al.
Publicado: (2018)

PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer
por: Flores, Orielyz, et al.
Publicado: (2017)

Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer
por: Gaudreault, Mathieu, et al.
Publicado: (2023)

The current status of prostate cancer treatment and PSMA theranostics
por: Uemura, Motohide, et al.
Publicado: (2023)

Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer
por: von Eyben, Rie, et al.
Publicado: (2023)

A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer
por: Alam, Mohammad R, et al.
Publicado: (2022)

Spotlight on PSMA as a new theranostic biomarker for bladder cancer
por: Tumedei, Maria Maddalena, et al.
Publicado: (2021)

Theranostics of Primary Prostate Cancer: Beyond PSMA and GRP-R
por: Schollhammer, Romain, et al.
Publicado: (2023)

How To Manage T3b Prostate Cancer in the Contemporary Era: Referee Position
por: Bossi, Alberto, et al.
Publicado: (2023)

Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer
por: Beauval, Jean-Baptiste, et al.
Publicado: (2016)

Timing and delay of radical prostatectomy do not lead to adverse oncologic outcomes: results from a large European cohort at the times of COVID-19 pandemic
por: Diamand, Romain, et al.
Publicado: (2020)

PSMA-Targeting Imaging and Theranostic Agents—Current Status and Future Perspective
por: Debnath, Sashi, et al.
Publicado: (2022)

PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook
por: Kirchner, Maximilian A., et al.
Publicado: (2021)

Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends
por: Kaewput, Chalermrat, et al.
Publicado: (2022)

Phase III Study of (18)F-PSMA-1007 Versus (18)F-Fluorocholine PET/CT for Localization of Prostate Cancer Biochemical Recurrence: A Prospective, Randomized, Crossover Multicenter Study
por: Olivier, Pierre, et al.
Publicado: (2023)

Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?
por: Sargos, Paul, et al.
Publicado: (2016)

Actualisation du risque lié à la corticothérapie en association à l’acétate d’abiratérone en période de pandémie COVID-19
por: Rozet, F., et al.
Publicado: (2021)

A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancers
por: Aide, Nicolas, et al.
Publicado: (2021)

Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
por: Plichta, Kristin A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_igpr6h65arvge8nrfun4s8gdih